Literature DB >> 17600726

Preoperative plasma levels of soluble tumor necrosis factor receptor type I (sTNF-RI) predicts adverse events in cardiac surgery.

C L Gelape1, M D Sanches, A L Teixeira, M M Teixeira, R Bráulio, I F Pinto, F Galdino, A L Ribeiro.   

Abstract

OBJECTIVE: The objective was to estimate the sTNF-RI preoperative measure in the identification of patients with bad outcome and death.
METHODS: We assessed prospectively sixty-two patients submitted electively to myocardial revascularization with ECC or heart valve surgery. The sTNF-RI levels were determined by the Sandwich-Type ELISA method before anesthetic induction. Clinical, surgical characteristics and sTNF-RI levels were compared among patients with good (group I, n=46) or bad outcome (group II, n=16--length of stay in the ICU for over 72 h or death).
RESULTS: No difference was found between the verified mortality (6.4%) and the predicted by EuroSCORE (3.0%), p=0.48. The sTNF-RI levels were higher in group II (1322) than group I (748) p=0.009 (levels >954, 69% sensitivity and 70% specificity for good outcome, 44% positive predicted value and 85% negative). The sTNF-RI levels were higher in patients who died (1556) versus (759) p=0.029, (levels >1230, 79% sensitivity, 75% specificity, 20% positive predicted value and 98% negative). In the multivariate logistic regression model sTNF-RI (OR=1.002, IC95% 1.000-1.005, p=0.014) and age (OR=1.083, IC95% 1.010-1.161, p=0.025) were independently related to the risk of bad outcome.
CONCLUSIONS: Basal levels of sTNF-RI yield prognostic information in patients who undergo heart surgery.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17600726     DOI: 10.1016/j.cyto.2007.05.007

Source DB:  PubMed          Journal:  Cytokine        ISSN: 1043-4666            Impact factor:   3.861


  1 in total

1.  Use of inflammatory molecules to predict the occurrence of fever in onco-hematological patients with neutropenia.

Authors:  A F Tibúrcio Ribeiro; V Nobre; L C Neuenschwander; A L Teixeira; S G Xavier; F D F Paula; M M Teixeira; J C A Teixeira; H Bittencourt
Journal:  Braz J Med Biol Res       Date:  2013-02-01       Impact factor: 2.590

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.